The Effects of Endoscopy Combined With Partial Splenic Artery Embolization in the Treatment of Cirrhosis With Esophageal and Gastric Varices Complicated With Hyperplenism or Splenomegaly:A Randomized Controlled Study.

Status: Unknown
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study was to compare the effects of partial splenic artery embolization combined with endoscopic treatment and endoscopic treatment alone on portal hypertension in cirrhosis with hyperplenism or splenomegaly in esophageal and gastric varices.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Patients aged between 18 and 75 years

• Patients who had recovered from an episode of VH or patients who had survived from acute VH and there was no bleeding for consecutive 5 days

• Patients with a diagnosis of liver cirrhosis and portal hypertension on clinical examination, laboratory test, and imaging or histological examination

• Patients with hypersplenism and thrombocytopenia (platelets \< 100,000/µL).

• Patients aged between 18 and 75 years

• Moderate to severe esophageal (and/or) gastric varices

• Patients with a diagnosis of liver cirrhosis and portal hypertension on clinical examination, laboratory test, and imaging or histological examination

• Patients with hypersplenism and thrombocytopenia (platelets \< 100,000/µL).

• Patients aged between 18 and 75 years

• Acute esophageal (and/or) gastric varices rupture and bleed \<5 days

• Patients with a diagnosis of liver cirrhosis and portal hypertension on clinical examination, laboratory test, and imaging or histological examination

• Patients with hypersplenism and thrombocytopenia (platelets \< 100,000/µL).

Locations
Other Locations
China
Qilu Hospital , Shandong University
Jinan
Time Frame
Start Date: 2020-09-25
Completion Date: 2022-12-31
Participants
Target number of participants: 368
Treatments
Experimental: Secondary prevention-1
Endoscopic therapy+ beta blockers
Experimental: Secondary prevention-2
Endoscopic therapy+ PSE+beta blockers
Experimental: Primary prevention-1
Endoscopic therapy
Experimental: Primary prevention-2
Endoscopic therapy+ PSE
Experimental: Acute bleeding-1
Endoscopic therapy+somatostatin
Experimental: Acute bleeding-2
Endoscopic therapy+PSE+somatostatin
Sponsors
Leads: Qilu Hospital of Shandong University

This content was sourced from clinicaltrials.gov